Vu Dinh Hoa, PhD A/Prof is Deputy Director of National Drug Information and Adverse Drug Event Monitoring Center of Viet Nam. He is also the lecturer in Hanoi University of Pharmacy and adjunct researcher at Vietnam National Children Hospital. His research of interest focus on optimizing the use of of antimicrobial agents including antibiotics, antifungal and antituberculosis drug based on PK/PD. He also have experience in dried blood spot for antituberculosis drugs, and therapeutic drug monitoring. He is supervising TDM teams in numbers of hospitals to develop TDM service for vancomycin and amikacin. His research team is working on the Model Informed Precision Dosing (SmartDoseAI®) for vancomycin using a web-based platform. He is also working with the Intensivists and Pediatricians to guide the antimicrobial treatment for critically ill patients, patients on Renal Replacement Therapy, neonates and paediatrics. He is an active member of the Regional Asian Paciffic Section of the International Association of TDM and Clnical Toxicology.

Prof. Zhao is a Doctoral Supervisor at Peking University and Macau University of Science and Technology, an Honorary Professor at the University of Manchester (UK), and a Member of the ACCP Board of Regents. As a leading expert in hospital pharmacy and clinical pharmacy, Prof. Zhao holds key positions in national and international organizations, including: Chinese Pharmacopoeia Commission (Member); Committee on Pharmacy Administration and Pharmacotherapy, National Health Commission of China (Member); Pharmaceutical Specialized Committee, Chinese Hospital Association (Chair); Committee on Patient Education and Science Popularization, Chinese Pharmacists Association (Chair); Hospital Pharmacy & Evidence-Based Pharmacy Committees, Chinese Pharmaceutical Association (Vice Chair); Therapeutic Drug Monitoring Research Committee, Chinese Pharmacological Society (Vice Chair). He serves as Editor-in-Chief of AJHP (Chinese Edition) and Deputy Editor-in-Chief of multiple prestigious journals, including China Pharmacy, Evaluation and Analysis of Drug-Use in Hospitals of China, Chinese Journal of New Drugs, Clinical Medication Journal and China Pharmaceuticals. Prof. Zhao's research focuses on precision medicine, therapeutic drug monitoring, and evidence-based pharmacy practice. He has led 38 research projects (including National Natural Science Foundation grants), published over 310 academic papers (3 ESI highly cited), and obtained 20 national invention patents. He has been honored with the Wu Jieping-Paul Janssen Award, China Pharmaceutical Association Science and Technology Award, and other distinguished accolades for his contributions to pharmaceutical sciences and clinical pharmacy.

Pieter De Cock is an Associate Professor in Clinical Pharmacology at the Faculty of Medicine and Health Sciences at Ghent University, Belgium, and a hospital pharmacist–clinical pharmacologist at Ghent University Hospital. At Ghent University, Pieter De Cock leads the Ghent Precision Dosing Research Unit, which focuses on (i) pharmacokinetic/pharmacodynamic (PK/PD) clinical research in special patient populations and, (ii) the clinical implementation of model-informed precision dosing (MIPD) tools. Currently, he is the principal investigator on three randomized clinical trials evaluating the added value of MIPD for anti-infective therapies. As a clinical pharmacist and member of the dosing advisory service at the hospital pharmacy of Ghent University Hospital, he is also involved in the day-to-day optimization of TDM-based dosing.

Anne-Grete Märtson is an assistant professor at the Leiden Academic Centre for Drug Research, Leiden University. She is leading a research group focusing on translational antiviral pharmacology. The group focuses on clinical studies, laboratory experiments such as the hollow fibre infection model and use computational methods to find best treatment regimens and translate results back to the clinical setting. The research topics include optimizing ganciclovir therapy for cytomegalovirus (CMV), therapeutic drug monitoring of antivirals, relating antiviral drug exposure to dose-related toxicity, dosing in extremes of organ function and in special populations, delay in antiviral therapy in SARS-CoV-2.

Dr. Mangalore is an Infectious Disease Physician and clinical researcher at Alfred Health and Monash University. Her research focuses on personalised antibiotic dosing using therapeutic drug monitoring and model-informed precision dosing to improve patient outcomes in critically ill patients. Dr Mangalore leads the beta-lactam TDM program at Alfred Health.